Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737

Cancer Biology and Therapy

Volumn 10, Issue 9, 2010, Pages 930-932

  Krystal, Geoffrey W ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABT 737; Actinomycin D; Bcl 2; Mcl 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; DACTINOMYCIN; PROTEIN BAK; PROTEIN BAX;

APOPTOSIS; ARTICLE; BIOAVAILABILITY; CANCER CELL CULTURE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PANCREAS CARCINOMA; PROTEIN EXPRESSION;

ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BIPHENYL COMPOUNDS; DACTINOMYCIN; DRUG SYNERGISM; HUMANS; NEOPLASMS; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 78549264505     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.9.13567     Document Type: Article

References (17)

1. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2008; 27:149-57.
2. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009; 15:1126-32.
3. Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, Cohen GM. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009; 16:1030-9.
4. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435:677-81. (Pubitemid 40825512)
5. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008; 68:3421-8.
6. Dai Y, Grant S. Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res 2007; 67:2908-11.
7. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007; 67:1176-83. (Pubitemid 46270776)
8. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10:389-99. (Pubitemid 44711953)
9. Zhou P, Qian L, Kozopas KM, Craig RW. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997; 89:630-43.
10. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ. Obligate role of antiapoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307:1101-4.
11. Thomas LW, Lam C, Edwards SW. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010; 584:2981-9.
12. Xu H, Krystal GW. Actinomycin D decreases Mcl-1 expression and acts synergistically with ABT-737 against small cell lung cancer cell lines. Clin Cancer Res 2010; 16:4382-91.
13. Olberding KE, Wang X, Zhu Y, Pan J, Rai SN, Li C. Actinomycin D synergistically enhances the efficacy of the BH3 mimetic ABT-737 by downregulating Mcl-1 expression. Cancer Biol Ther 2010; 10:918-29.
14. Tattersall MH, Sodergren JE, Dengupta SK, Trites DH, Modest EJ, Frei E, 3rd. Pharmacokinetics of actinomycin D in patients with malignant melanoma. Clin Pharmacol Ther 1975; 17:701-8.
15. Veal GJ, Cole M, Errington J, Parry A, Hale J, Pearson AD, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005; 11:5893-9.
16. Mondick JT, Gibiansky L, Gastonguay MR, Skolnik JM, Cole M, Veal GJ, et al. Population pharmacokinetic investigation of actinomycin-D in children and young adults. J Clin Pharmacol 2008; 48:35-42. (Pubitemid 350292266)
17. Choong ML, Yang H, Lee MA, Lane DP. Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy. Cell Cycle 2009; 8:2810-8.